IATI Biomed 2015: "We realize Israel has vast experience"May. 17, 2015
Pfizer's representative at the 2015 IATI Biomed conference in Tel Aviv was president of worldwide research and development (WRD), portfolio strategy and investment committee chairman, and executive VP Mikael Dolstein. As part of his job, he is very involved in cooperative ventures with external parties. "I was very much looking forward to my visit to Israel, where I met companies, academic groups, and venture capital funds in order to see how our cooperative ventures in innovation can be extended to the Israeli biomedical community," he says.
"Globes": What lies behind Pfizer's acquisition strategy and focus?
Dolstein: "Our focus is currently on cancer, vaccinations, heart disease, inflammatory diseases, rare diseases, and mental and brain diseases. We also have a division for established products not necessarily in these areas and a generics division. We decided to focus our innovation, because we realized that knowledge of a disease we treat from the beginning of its development process until we have a profound understanding of the science, the marketing stage, and a close connection with the patients and doctors were important to us. We are already well-positioned in all of these areas from the beginning of the process until its end, except in neurology. There, we had a past, and we're now building a future".
For the full Globes interview click here.